Arysta Licenses Meiji’s Insecticide for Rice in India

Arysta LifeScience, a Platform Specialty Products Corp. company, announced it has finalized an exclusive licensing agreement with Meiji Seika Pharma Co., Ltd. to develop and commercialize formulations of Meiji’s Flupyrimin insecticide technology for applications in rice in India.

Flupyrimin is a new proprietary active ingredient that provides effective control of damaging pests in rice and other important crops.

Advertisement

Rice is a major staple crop for half the global population. As the second-largest rice producer in the world, India accounts for 21% of the world’s production of the crop and harvests 44 million hectares annually. New crop protection technology such as Flupyrimin has the potential to help reduce the estimated 45% gross loss of crops due to pests and diseases.

Flupyrimin, discovered and developed by Meiji, has the distinctive characteristic of controlling both stem borers in the early cultivation stage and plant hoppers in the mid to late stage with one application. The product also shows control against resistant insects.

“We believe India rice growers will benefit from this unique one-pass solution to control some of the most damaging insect pests, which is estimated to affect over 30 million treated hectares of rice in the country every year,” says Hisaya Kobayashi, Business Unit Head – Asia, Arysta LifeScience. “This licensing partnership with Meiji Seika Pharma underlines our global strategy of collaboration to deliver innovative specialty crop protection solutions tailored for major crops.”

Arysta LifeScience intends to initially launch two proprietary formulations of Flupyrimin with distinct value propositions for the rice market.

“Flupyrimin is an innovative technology created by our company’s research, and we are excited to have Arysta LifeScience as a development and commercial partner to deliver this solution to rice growers across India,” says Shuichi Hashimoto, Executive Officer and Managing Director – Agricultural & Veterinary Division, Meiji Seika Pharma.

Meiji Seika Pharma Co., Ltd., based in Tokyo, Japan, is a fully owned subsidiary of Meiji Holdings Co. Ltd.